Tiziana Life Sciences Com (TLSA) Stock News

Tiziana Life Sciences (NASDAQ: TLSA) has achieved a significant milestone by dosing the first patient with moderate Alzheimer's disease using intranasal foralumab at Brigham and Women's Hospital in Boston. The treatment, a fully human anti-CD3 monoclonal antibody, aims to reduce brain inflammation through a unique mechanism that stimulates T regulatory cells to cross the blood-brain barrier and reduce neuroinflammation of glial cells.

This approach differs from traditional beta amyloid removal or tau protein reduction methods. The study is part of a broader development program that received a $4 Million NIH grant in September 2024. Dr. Howard Weiner, the Principal Investigator, notes that there are currently no approved drugs for moderate Alzheimer's disease, highlighting the potential significance of this novel treatment approach.

Tiziana Life Sciences (NASDAQ: TLSA) has expanded its Phase 2 clinical trial for intranasal foralumab in non-active secondary progressive multiple sclerosis (SPMS) to include prestigious medical centers across the Northeast United States. The trial now encompasses Yale University, Johns Hopkins University, Cornell University, University at Buffalo, University of Massachusetts, and Thomas Jefferson University.

The strategic selection of Northeast locations enables all trial participants to receive PET scans at a single imaging site at Invicro in New Haven, Connecticut, minimizing scan variability. This expansion is particularly significant as non-active SPMS currently has no FDA-approved therapeutic options. The company's intranasal foralumab offers a unique approach by targeting inflammation and modulating the immune system without systemic immune suppression.

Tiziana Life Sciences (NASDAQ: TLSA) has received a grant from the ALS Association through the Hoffman ALS Clinical Trial Awards Program to fund a 20-patient clinical trial of intranasal foralumab, their lead development candidate. The trial will evaluate safety and early-stage disease improvement parameters in ALS patients. Foralumab, a fully human anti-CD3 monoclonal antibody, has shown promise in treating Multiple Sclerosis, with positive results in 10 patients under an Expanded Access Program. The FDA has approved enrollment of 20 additional patients in this program.

Tiziana Life Sciences (Nasdaq: TLSA) announced its participation in BIO-Europe 2024, scheduled for November 4-6 in Stockholm, Sweden. The company will showcase its recent clinical advancements, particularly focusing on its combination study data involving Ozempic, a GLP-1 agonist, and its lead candidate, intranasal foralumab, a fully human anti-CD3 monoclonal antibody.

CEO Ivor Elrifi highlighted the conference as an opportunity to present their latest clinical findings and engage with potential partners. The company aims to leverage this platform to discuss strategic partnerships and showcase their therapeutic pipeline development, following a successful fundraising round that supports their ongoing Phase 2 studies.

Tiziana Life Sciences announced a registered direct offering of 5,263,158 common shares at $0.95 per share, raising approximately $5 million in gross proceeds. The company also issued an option for investors to acquire an additional 5,263,158 shares at the same price within 75 days, potentially raising another $5 million. The proceeds will fund Phase 2a clinical trials for intranasal foralumab in multiple sclerosis patients, accelerate Alzheimer's disease research, develop foralumab for other indications, and support working capital needs. The offering is expected to close around November 1, 2024.

Tiziana Life Sciences (TLSA) announced positive results from a study combining nasal anti-CD3 (foralumab) with semaglutide (Ozempic). The research, conducted at Brigham and Women's Hospital, demonstrated that the combination improves liver homeostasis and reduces inflammation in diet-induced obesity models. Key findings show synergistic effects in promoting liver health, with the combination therapy resulting in significant reductions in pro-inflammatory cytokines and improvements in liver markers associated with metabolic regulation. The study suggests this novel approach could effectively combat obesity-related inflammation and liver dysfunction.

Tiziana Life Sciences (NASDAQ: TLSA) has announced a $4 million grant from the National Institutes of Health to study intranasal anti-CD3 for Alzheimer's disease treatment. The grant, awarded to Dr. Howard Weiner at Brigham and Women's Hospital, will fund preclinical and clinical studies over several years. Tiziana's proprietary anti-CD3 formulation, administered intranasally, aims to modulate immune system activity and reduce neuroinflammation in Alzheimer's patients. This funding supports Tiziana's broader strategy to explore anti-CD3 in various autoimmune and inflammatory diseases. The company plans to initiate first-in-human clinical trials for Alzheimer's Disease in the coming months, marking a significant step towards potential regulatory approval and commercialization.

Tiziana Life Sciences (Nasdaq: TLSA) has appointed Ivor Elrifi as its new Chief Executive Officer, effective immediately. Elrifi, formerly the global head of the Patent Group at Cooley, brings extensive experience in intellectual property strategies and business development in the biotech and pharma sectors. Tiziana, focused on developing immunomodulation therapies, aims to accelerate its clinical trials for intranasal foralumab in treating non-active Secondary Progressive Multiple Sclerosis, Alzheimer's Disease, and ALS under Elrifi's leadership.

Gabriele Cerrone, Founder and Executive Chairman, expressed confidence in Elrifi's ability to create substantial value for the company. Elrifi's background includes guiding clients in strategic transactions and M&A involving major pharmaceutical companies. He succeeds Cerrone, who will continue as Executive Chairman, focusing on advancing Tiziana's scientific agenda.

Tiziana Life Sciences (TLSA) has regained compliance with Nasdaq's minimum bid price rule, ensuring its continued listing on the Nasdaq Capital Market. The company, which develops immunomodulation therapies, had been notified of non-compliance on July 19, 2023, when its stock failed to maintain a closing bid price of $1.00 or more for 30 consecutive business days. Tiziana successfully met the requirement by maintaining a minimum closing bid price of $1.00 or more for at least ten consecutive trading days, achieving this on August 9, 2024. As a result, the previously scheduled hearing before the Hearings Panel has been cancelled, and Tiziana's securities will continue to be listed and traded on Nasdaq.